Patents by Inventor Masashi Kishida

Masashi Kishida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Developing apparatus, developer for electrophotographic image formation, electrophotographic image forming method, and electrophotographic image forming apparatus
    Patent number: 11934145
    Abstract: A developing apparatus includes an electrostatic latent image bearer, a developing sleeve, a case, and an air filter. The case accommodates a two-component developer and the developing sleeve. The air filter is attached to the case. The air filter has a thickness of 2 to 20 mm and has a density gradient with a pressure loss of 2 to 40 Pa at a wind speed of 10 cm/s. The air filter forms an airflow sucked into the case from a gap between the developing sleeve and the case and forms an airflow discharged from the case through the air filter. The two-component developer accommodated in the case contains a magnetic particle a surface of which is coated with a resin layer. The resin layer contains at least one type of chargeable particle.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: March 19, 2024
    Assignee: Ricoh Company, Ltd.
    Inventors: Minoru Masuda, Tohru Suganuma, Masashi Nagayama, Hiroyuki Kishida, Kento Takeuchi, Kaede Masuko, Tomomi Suzuki, Takuya Suganuma, Kazuki Yogosawa
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8906852
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: December 9, 2014
    Assignee: MethylGene Inc.
    Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frédéric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20140315801
    Abstract: This invention relates to methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions using compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to the methods of treatment which utilize compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling.
    Type: Application
    Filed: June 18, 2014
    Publication date: October 23, 2014
    Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frederic Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20140179632
    Abstract: This invention relates to methods for inhibiting kinase activity and/or inhibiting angiogenesis and/or treating a disease responsive to inhibition of kinase activity and/or treating a cell proliferative disease and/or treating an ophthalmic disease, condition or disorder treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions comprising administering novel compounds that inhibit protein tyrosine kinase activity.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: MethylGene Inc.
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8759522
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: June 24, 2014
    Assignee: Methylgene Inc.
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8729268
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 20, 2014
    Assignee: MethylGene Inc.
    Inventors: Michael Mannion, Stéphane Raeppel, Stephen William Claridge, Frédéric Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Bicyclic derivatives as CETP inhibitors
    Patent number: 8410275
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: April 2, 2013
    Assignee: Novartis AG
    Inventors: Masashi Kishida, Naoko Matsuura, Hidetomo Imase, Yuki Iwaki, Ichiro Umemura, Osamu Ohmori, Eiji Kawahara
  • BICYCLIC DERIVATIVES AS CETP INHIBITORS
    Publication number: 20120225874
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.
    Type: Application
    Filed: May 17, 2012
    Publication date: September 6, 2012
    Applicant: NOVARTIS AG
    Inventors: Masashi KISHIDA, Naoko MATSUURA, Hidetomo IMASE, Yuki IWAKI, Ichiro UMEMURA, Osamu OHMORI, Eiji KAWAHARA
  • Bicyclic derivatives as CETP inhibitors
    Patent number: 8232403
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: July 31, 2012
    Assignee: Novartis AG
    Inventors: Masashi Kishida, Naoko Matsuura, Hidetomo Imase, Yuki Iwaki, Ichiro Umemura, Osamu Ohmori, Eiji Kawahara
  • Inhibitors of Protein Tyrosine Kinase Activity
    Publication number: 20110257100
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 20, 2011
    Inventors: Stëphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frëdëric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of Protein Tyrosine Kinase Activity
    Publication number: 20110098293
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 28, 2011
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20110077240
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Application
    Filed: December 9, 2010
    Publication date: March 31, 2011
    Inventors: Michael Mannion, Stéphane Raeppel, Stephen William Claridge, Frédéric Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Organic Compounds
    Publication number: 20100173896
    Abstract: The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, to the manufacture and to the use thereof.
    Type: Application
    Filed: March 16, 2010
    Publication date: July 8, 2010
    Inventors: JUNICHI SAKAKI, KAZUHIDE KONISHI, MASASHI KISHIDA, MASAAKI KIMURA, HIDEFUMI UCHIYAMA, HIRONOBU MITANI
  • 11-phenyl-dibenzodiazepine derivatives as RXR-antagonists
    Patent number: 7709470
    Abstract: The present invention relates to novel benzodiazepine compounds exhibiting RXR-antagonist efficacy, for delaying progression of, preventing or treating a condition or disease being associated with RXR-antagonism, in particular selected from diabetes, complication of diabetes such as retinopathy, nephropathy, neuropathy, and hyperlipidemia, obesity, dyslipidemia, and osteoporosis.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: May 4, 2010
    Assignee: Novartis AG
    Inventors: Junichi Sakaki, Kazuhide Konishi, Masashi Kishida, Masaaki Kimura, Hidefumi Uchiyama, Hironobu Mitani
  • Compounds and compositions useful as cathepsin S inhibitors
    Patent number: 7704996
    Abstract: The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: April 27, 2010
    Assignee: Novartis AG
    Inventors: Terance William Hart, Allan Hallett, Fumiaki Yokokawa, Hajime Hirao, Takeru Ehara, Atsuko Iwasaki, Junichi Sakaki, Keiichi Masuya, Masashi Kishida, Osamu Irie
  • Organic Compounds
    Publication number: 20100076021
    Abstract: The present invention provides a compound of formula (I): said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Application
    Filed: November 13, 2007
    Publication date: March 25, 2010
    Inventors: Hidetomo Imase, Masashi Kishida
  • Organic Compounds
    Publication number: 20100041705
    Abstract: The present invention provides a compound of formula (I): said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.
    Type: Application
    Filed: November 13, 2007
    Publication date: February 18, 2010
    Inventors: Hidetomo Imase, Masashi Kishida
  • Bicyclic derivatives as CETP inhibitors
    Publication number: 20090227580
    Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay progression to overt to diseases in which CETP is involved.
    Type: Application
    Filed: May 8, 2007
    Publication date: September 10, 2009
    Inventors: Masashi Kishida, Naoko Matsuura, Hidetomo Imase, Yuki Iwaki, Ichiro Umemura, Osamu Ohmori, Eiji Kawahara
  • CETP inhibitors
    Publication number: 20090075968
    Abstract: The present invention relates to a compound of formula or a pharmaceutically acceptable salt thereof, wherein the variables are as defined.
    Type: Application
    Filed: December 27, 2006
    Publication date: March 19, 2009
    Inventors: Junichi Sakaki, Masashi Kishida, Naoko Matsuura, Ichiro Umemura, Eiji Kawahara, Ken Yamada, Kazuhide Konishi, Yuki Iwaki, Hidetomo Imase, Takahiro Miyake
  • COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS
    Publication number: 20090048230
    Abstract: The present invention relates to the use of a 2-cyanopyrimidine compound of the formula wherein R1, R2, R3 and X are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in tautomeric form, as an inhibitor of the activity of cathepsin S.
    Type: Application
    Filed: August 16, 2005
    Publication date: February 19, 2009
    Inventors: Terance William Hart, Allan Hallett, Fumiaki Yokokawa, Hajime Hirao, Takeru Ehara, Atsuko Iwasaki, Junichi Sakaki, Keiichi Masuya, Masashi Kishida, Osamu Irie